Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
Magnetic Resonance Imaging of Brain Iron in Health and Disease
J Neurol Sci 134:19-26,1, Vymazal,J.,et al, 1995
The Differential Diagnosis of Longitudinally Extensive Transverse Myelitis
Mult Scler 18:271-285, Kitley, J.L.,et al, 2012
Significance of T2 Lesions in Multiple Sclerosis: A 13-Year Longitudinal Study
Ann Neurol 60:236-242, Rudick,R.A.,et al, 2006
MRI T2 Hypointensity of the Dentate Nucleus is Related to Ambulatory Impairment in Multiple Sclerosis
J Neurol Sci 234:17-24, Tjoa,C.W.,et al, 2005
T2 Hypointensity in the Deep Gray Matter of Patients With Multiple Sclerosis
Arch Neurol 59:62-68, Bakshi,R.,et al, 2002
Multiple Sclerosis and Magnetic Resonance Imaging
Arch Neurol 58:35-36, Racke,M.K.,et al, 2001
A Longitudinal MRI Study of Histopathologically Defined Hypointense Multiple Sclerosis Lesions
Ann Neurol 49:793-796, Bitsch,A.,et al, 2001
Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis,Relation to Inflammatory Activity
Arch Neurol 56:345-351, van Walderveen,M.A.A.,et al, 1999
Relevance of Hypointense Lesions on Fast Fluid-Attenuated Inversion Recovery MR Images as a Marker of Disease Severity in Cases of Multiple Sclerosis
AJNR 20:813-820, Rovaris,M.,et al, 1999
Interferon-B-1a in Relapsing-Remitting Multiple Sclerosis:Effect on Hypointense Lesion Volume on T1 Weighted Images
JNNP 67:579-584, Gasperini,C.,et al, 1999
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Assessment of MRI Criteria for a Diagnosis of MS
Neurol 43:905-909, Offenbacher,H.,et al, 1993
Multiple Sclerosis:Specificity of MR for Diagnosis
Radiology 178:447-451, Yetkin,F.Z.,et al, 1991
What Do We Really See When We Look at Magnetic Resonance Images?
Ann Neurol 62:207-208, Filippi,M. &Hartung,H.-P., 2007
Paramagnetic Rim Lesions are Specific to Multiple Sclerosis:An International Multicenter 3T MRI Study
Ann Neurol 88:1034-1042, Maggi,P.,et al, 2020
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis
JAMA Neurol 76:1446-1456, Sinnecker, T.,et al, 2019
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Value of the Central Vein Sign at 3T to Differentiate MS from Seropositive NMOSD
Neurol 90:e1183-e1190, Cortese, R.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
The Thalamus and Multiple Sclerosis
Neurol 80:210-219, Minagar, A.,et al, 2013
Longitudinally Extensive Transverse Myelitis with and Without Aquaporin 4 Antibodies
JAMA Neurol 70:1375-1381, Kitley, J.,et al, 2013
Distinct Lesion Morphology at 7-T MRI Differentiates Neuromyelitis Optica from Multiple Sclerosis
Neurol 79:708-714, Sinnecker, T.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Longitudinally Extensive Myelopathy in Caucasians: A West Australian Study of 26 Cases from the Perth Demyelinating Diseases Database
JNNP 81:209-212, Qiu,W.,et al, 2010
An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008
Quantitative Assessment of Iron Accumulation in the Deep Gray Matter of Multiple Sclerosis by Magnetic Field Correlation Imaging
AJNR 28:1639-1644, Ge,Y.,et al, 2007
Three Subsequent Single Doses of Gadolinum Chelate for Brain MR Imaging in Multiple Sclerosis
AJNR 24:658-662, Sardanelli,F.,et al, 2003
Comparison of Triple Dose vs Std Dose Gadolinium-DTPA for Detect of MRI Enhanc Lesions in Pts with MS
Neurol 46:379-384, Filippi,M.,et al, 1996
Triple Dose of Gadolinium-DPTA and Delayed MRI in Patients with Benign Multiple Sclerosis
JNNP 60:526-530, Filippi,M.,et al, 1996
Clinicopath Conf
Distinguishing Acute Disseminated Encephalomyelitis from Multiple Sclerosis, BMJ 313:802-8041996., , 1996
Comparison of Triple Dose vs Std Dose Gadolinium-DTPA for Detect of MRI Enhanc Lesions in Pts with Primary Progr MS
JNNP 59:540-544, Filippi,M.,et al, 1995
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis
Ann Neurol 96:846-854, Marrodan,M.,et al, 2024
Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease
Ann Neurol 96:1086-1091, Fadda,G.,et al, 2024
Differentiating Multiple Sclerosis from AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease with Imaging
Neurol 100:e308-e323, Cortesa,R.,et al, 2023
Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder
Neurol 100:e1418-e1432, Cacciaguerra, L.,et al, 2023
Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis
Neurol 97:e414-e422, Jolliffe, E.A.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Radiologically Isolated Syndrome: A Review for Neuroradiologists
AJNR 41:1542-1549, Hosseiny, M.,et al, 2020
"Better Explanations" in Multiple Sclerosis Diagnostic Workup
Neurol 92:e2527-e2537, Calabrese, M.,et al, 2019
Evaluation of Idiopathic Transverse Myelitis Revealing Specific Myelopathy Diagnoses
Neurol 90:e96-102, Zalewski, N.L.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018
Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients with a Typical Clinically Isolated Syndrome
JAMA Neurol 75:1392-1398, Van Der Vuurst De Vries, R.M.,et al, 2018
Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017